Evaluation of CNS-Active Drugs for Worldwide Submission

 

In this complimentary webinar, Dr. Beatrice Setnik and Dr. Andy Mead take a comprehensive look at the key differences between the EMA and FDA drug development requirements when evaluating CNS-active drugs for abuse potential, as well as the need for a controlled substance designation.

Watch the webinar.

Watch the webinar Evaluation of CNS-Active Drugs for Worldwide Submission

Questions? Speak with our scientists.

You may also be interested in the following:


Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.